The vaccine initially showed promising results in preclinical evaluations in NHP models in terms of attenuating the infection in the acute phase, the maintenance and recovery of CD4+ T cells, and the control of viremia during the chronic phase of infection (Shiver et al., 2002). This evidence concerns the gene CD4 and infection.